Pfizer Eyes Consumer Unit Spin-Off Or Sale Price North of $10 Bil.
This article was originally published in The Tan Sheet
Executive Summary
Pfizer has "no interest" in separately divesting individual products from its consumer division, CEO Hank McKinnell said during a Feb. 10 analysts presentation
You may also be interested in...
J&J Washes Hands Of Purell As GOJO Eyes Consumer Segment Growth
Johnson & Johnson sells the Purell Hand Sanitizer brand, marking a major consumer health product divestment as the firm seeks to rebound from a troubled year for its consumer business.
J&J Picks Up Listerine, Nicorette With $16.6 Bil. Purchase Of Pfizer OTCs
Johnson & Johnson's successful bid to acquire Pfizer Consumer Healthcare extends the firm's reach in the global OTC market and provides entry into several new product categories
Pfizer Weighs Options For OTC Division As Investors Line Up For Purchase
While Pfizer considers whether to sell its Consumer Healthcare unit or spin it off to shareholders, potential buyers are placing bids with an eye toward an early June deadline